Black Diamond Therapeutics Income Statement (2018-2021) | BDTX

Income Statement Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021
Operating items
Research & Development 5.65M5.63M7.46M10.17M12.93M17.76M26.72M27.63M19.66M
Selling, General & Administrative 1.35M2.51M2.88M4.86M5.55M5.43M8.00M7.74M6.42M
Other Operating Expenses 3.05M3.84M12.88M
Operating Expenses 3.05M3.84M7.00M8.15M10.34M12.88M15.03M18.48M23.18M34.72M35.36M26.08M
Operating Income -3.05M-3.84M-7.00M-8.15M-10.34M-12.88M-15.03M-18.48M-23.18M-34.72M-35.36M-26.08M
EBIT -3.05M-3.84M-7.00M-8.15M-10.34M-12.88M-15.03M-18.48M-23.18M-34.72M-35.36M-26.08M
Non-operating items
Interest & Investment Income 0.01M0.00M0.44M0.88M1.16M1.25M0.95M0.78M0.59M
Other Non Operating Income -5.30M-1.12M0.02M-0.42M-0.59M-0.70M-0.58M-0.49M-0.38M
Non Operating Income -5.29M-1.12M0.47M0.46M-0.59M0.56M-0.58M-0.49M-0.38M
Net income details
EBT -3.05M-3.84M-6.99M-8.15M-9.90M-12.88M-14.15M-17.32M-21.93M-33.77M-34.59M-25.49M
Profit After Tax -3.07M-3.83M-12.29M-9.27M-9.88M-12.14M-14.57M-17.91M-22.63M-34.35M-35.08M-25.87M
Income from Continuing Operations -3.05M-3.84M-6.99M-8.15M-9.90M-12.88M-14.15M-17.32M-21.93M-33.77M-34.59M-25.49M
Consolidated Net Income -3.05M-3.84M-6.99M-8.15M-9.90M-12.88M-14.15M-17.32M-21.93M-33.77M-34.59M-25.49M
Income towards Parent Company -3.05M-3.84M-6.99M-8.15M-9.90M-12.88M-14.15M-17.32M-21.93M-33.77M-34.59M-25.49M
Net Income towards Common Stockholders -3.05M-3.84M-6.99M-8.15M-9.90M-12.88M-14.15M-17.32M-21.93M-33.77M-34.59M-25.49M
Additional items
EPS (Basic) -1.51-1.87-5.99-4.50-4.63-0.54-0.41-0.50-0.67-0.93-0.95-0.71
EPS (Weighted Average and Diluted) -0.54-0.41-0.50-0.63-0.93-0.95-0.71
Shares Outstanding (Weighted Average) 2.02M2.04M2.05M2.07M2.08M23.70M35.91M35.93M32.91M36.12M36.18M36.22M
Shares Outstanding (Diluted Average) 23.70M35.91M35.93M32.91M36.12M36.18M36.22M
EBITDA -3.05M-3.84M-12.29M-9.27M-9.88M-12.88M-13.56M-18.05M-22.89M-34.48M-35.15M-26.42M
Interest Expenses 0.00M